CAS 219832-49-2

Formula: C27H25N3O4S2

InChI: InChI=1S/C27H25N3O4S2/c1-20-11-15-23(16-12-20)35(31,32)29-25-8-4-3-7-22(25)19-28-26-9-5-6-10-27(26)30-36(33,34)24-17-13-21(2)14-18-24/h3-19,29-30H,1-2H3

InChI key: FLDBNMYJUMAXDQ-UHFFFAOYSA-N

SMILES: CC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C=NC3=CC=CC=C3NS(=O)(=O)C4=CC=C(C=C4)C

MP-A08

CAS: 219832-49-2

MP-A08 selectively inhibits SPHK1; targets SphK1 & SphK2 with Ki of 6.9 μM & 27 μM, respectively.

Formula: C₂₇H₂₅N₃O₄S₂

Purity: 97.44%

Color and Shape: Solid

Molecular weight: 519.64

Ref: TM-T16128

4-Methyl-N-(2-((2-((4-methylphenyl)sulfonamido)benzylidene)amino)phenyl)benzenesulfonamide

CAS: 219832-49-2

Formula: C₂₇H₂₅N₃O₄S₂

Purity: 97%

Color and Shape: Solid

Molecular weight: 519.6351

Ref: IN-DA00BF7P

MP-A08

CAS: 219832-49-2

MP-A08

Formula: C₂₇H₂₅N₃O₄S₂

Purity: ≥95%

Molecular weight: 519.64

Ref: 54-BUP13155

MP-A08

CAS: 219832-49-2

MP-A08 is a potent inhibitor drug that blocks the activity of epidermal growth factor receptor (EGFR). It has been shown to inhibit the growth of cancer cells in vitro and in vivo. MP-A08 was also found to have synergistic effects with cancer drugs, such as doxorubicin, cisplatin, 5-fluorouracil, and tamoxifen. MP-A08 may be used for the treatment of cardiac and prostate cancer.

Formula: C₂₇H₂₅N₃O₄S₂

Purity: Min. 95%

Molecular weight: 519.64 g/mol

Ref: 3D-UIA83249